Polycythemia vera (PV)
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
... Abstract: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by erythrocytosis and the presence of Janus kinase (JAK) 2V617F or similar ...of PV, the challenges ...
13
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
... Background: Pegylated interferon alfa‑2a (PEG‑IFN‑α‑2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia ...
13
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
... of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by Prchal and Axelrad in the ...of PV pathogenesis and ...
11
Serum Levels of Testosterone in Patients with Polycythemia Vera
... with polycythemia vera (PV) than in those with reac- tive erythrocytosis (RE) without the Janus Kinase 2 (JAK2) V167F gene mutation ...[6]. PV is classified as a myeloproliferative neoplasm ...
6
<p>Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib</p>
... Abstract: Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelo fi brosis and polycythemia vera (PV). Despite its ...
5
Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
... with polycythemia vera (PV) have a higher mortality risk compared with the general popula- tion, primarily driven by cardiovascular disease, thrombotic events (TEs), and hematologic ...in PV ...
6
<p>Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes</p>
... Abstract: Polycythemia vera is a Philadelphia-negative chronic myeloproliferative neo- plasm, characterized by erythrocytosis, which is unique, compared to essential thrombocy- tosis and primary myelo fi ...
13
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
... referred to the local department of hematology because of leukopenia and thrombocytopenia. A bone marrow biopsy showed mildly increased total cellularity (55%), increased numbers of megakaryocytes, no significant in- ...
6
Case Report on Feline Polycythemia Vera
... Polycythemia vera has been reported as a known condition in cats as early as ...setting. Polycythemia vera is relatively uncommon in dogs and cats, but should still be considered in cases of ...
7
Polycythemia vera The in vitro response of normal and abnormal stem cell lines to erythropoietin
... indicated that normal and polycythemia vera cells are capable of responding to ESF in vitro. In selected patients, this technique permits analysis of the ratios of normal to abnormal cells during the course ...
5
OXYGEN SATURATION OF STERNAL MARROW BLOOD IN POLYCYTHEMIA VERA
... Oxygen content, capacity, and percentage saturation of bone marrow blood were determined in man in a group of controls and in patients with polycythemia vera, anemia, and anoxic anoxia..[r] ...
6
Erythropoietin receptors in polycythemia vera
... in PV are exquisitely sensitive to EP and EP dependent, and others suggesting that PV progenitors are EP ...nM), PV ECFC show a single class of 851 low affinity EP-R with Kd = ...driven) ...
6
Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden
... high-risk PV and ET using PegINFα versus HU; (2) patients who participated in MPD-RC 111 for PV and ET patients intolerant or refractory to hydroxyurea and patients with Budd Chi- ari syndrome (both trials ...
9
Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.
... (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), and chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clonal ...
9
DETECTION OF JAK-2 MUTATION BY PCR TECHNIQUE IN CHRONIC MYELOPROLIFERATIVE DISORDERS
... include polycythemia Vera (PV), esssential thrombocythemia (ET), chronic idiopathic myelofibrosis (CIMF) and chronic myeloid leukemia (CML), plus rare types such as chronic neutrophilic leukemia ...
7
Clinical Profile of Philadelphia Negative Myeloproliferative Neoplasms in India.
... of polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis ...was polycythemia vera, 42%, followed by PMF 21% and ET ...of PV and ...Conclusions: ...
87
Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada
... The myeloproliferative neoplasms (MPNs) are clonal myeloid malignancies of the bone marrow classified by their unique genetic etiology and hematological histo- morphologic features. The broadest classification is by ...
5
Studies on N5 methyltetrahydrofolate homocystein methyltransferase in normal and leukemia leukocytes
... of methyltransferase activity were detected in normal granulocytes and cells from patients with chronic myelocytic leukemia CML and polycythemia vera PV when assayed in the standard syst[r] ...
10
Myeloproliferative neoplasms (MPNs) – Part 1: An overview of the diagnosis and treatment of the “classical” MPNs
... Myeloproliferative neoplasms (MPNs) are rare, yet potentially life-threatening, disorders caused by overproliferation of bone mar- row stem cells. The symptom burden experienced by patients with the BCR-ABL1-negative ...
8
Original Article Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients
... with Polycythemia Vera (PV), 24 cases with Essential Thrombocytosis (ET) and 16 cases with Idiopathic Myelofibrosis (IMF) and 20 cases as a control group which represented as; (10 cases with ...
5